In an interview today with co-founder and CEO of Cord Blood America, Matthew Schissler discussed its 2010 business strategies. The interview was completed by analyst Francis Gaskins.
In the interview the three pillars of success for Cord Blood America in 2010 were stressed by Schissler. Those three pillars consist of organic growth, acquisitions, and diversification of the revenue stream.
Cord Blood America's CEO also stressed that the Company has the funds in place for acquisitions in 2010 and believes the market is right to add companies to the Cord Blood America family. "We have in place investor-friendly financing, debt that can be paid back in cash rather than stock," Mr. Schissler said.
Best Damn Penny Stocks, a leading financial publication, is pleased to alert investors of stocks on the move.
Sign Up for our Free Stock Newsletter
About Cord Blood America
Cord Blood America (OTC Bulletin Board: CBAI) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders.
Sign up for the free Best Damn Penny Stocks newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website
About Best Damn Penny Stocks
Best Damn Penny Stocks is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer
